Le Lézard
Classified in: Environment, Transportation, Health, Science and technology
Subjects: PDT, SVY

Cole-Parmer Re-launches Fluid Handling Product Line


VERNON HILLS, Ill., April 8, 2024 /PRNewswire/ -- Cole-Parmer, an Antylia Scientific company, is launching an all-new range of industry-leading fluid handling solutions initially comprised of tubing, fittings, parts, and accessories to suit a diverse array of research and production needs.

Cole-Parmer Re-launches Fluid Handling Product Line

Tubing options include specialized formulations for use in pharmaceutical, clinical, automotive, water treatment and food & beverage applications. Fittings are made from high-grade PVC/PBA-free materials.

To complement these high-quality products, Cole-Parmer is committed to providing responsive customer service and ongoing technical support. The company's dedicated specialists have decades of experience catalyzing innovation across many sectors and can collaborate with customers to develop customized solutions.

Jon Salkin, CEO of Cole-Parmer, commented: "Cole-Parmer is excited to be back in fluid handling, leading with our well-established brand and our passion for customer solutions. We look forward to continuing to expand our product line to include peristaltic pumps, complex assemblies and other related consumables to service the bioprocessing & broader fluid handling industry."

About Cole-Parmer

Cole-Parmer, an Antylia Scientific company, is a trusted global leader in laboratory essentials. We deliver a portfolio of reliable equipment and consumables to help speed scientific discovery in life science, clinical, academic and research laboratories. Since 1955, we have been known for our knowledgeable team of scientific experts who are devoted to providing one-on-one guidance in product selection, usage, and troubleshooting, enabling laboratories to run efficiently throughout the world. We provide a true one-stop-shop supply chain solution by curating a portfolio of unique industry-leading brands. Cole-Parmer is a division of Antylia Scientific, an operating company of premier life science and diagnostic brands, including Cole-Parmer, Environmental Express, and Zeptometrix.

SOURCE Cole-Parmer


These press releases may also interest you

at 17:00
Zepp Health Corporation Announces Receipt of NYSE Non-compliance Letter Regarding ADS Trading Price
Zepp Health Corporation ("Zepp" or the "Company") , a global leader in smart wearables and health technology, today announced that it has received a letter from the New York Stock Exchange (the "NYSE") dated April 30, 2024, notifying Zepp that it is...

at 16:55
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
Revelation Biosciences, Inc. (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ended March...

at 16:55
Maple Counseling Announces Pioneering Partnership with Saban Community Clinic to Expand Access to Mental Health Services
Maple Counseling has partnered with Saban Community Clinic to launch the Saban Partnership Program, aimed at enhancing access to mental healthcare for underserved communities. This initiative includes the introduction of four bilingual Associate...

at 16:35
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
Bristol Myers Squibb today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC). CheckMate -73L evaluated...

at 16:35
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung...

at 16:35
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a...

More news about Health...


News published on and distributed by: